Search - tctmd.com

Displaying 121 - 140 of 144

Sort: Relevancy | Date

News Conference News THT 2023

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

Todd Neale

March 20, 2023

Presentation THT 2023

FDA Guidance on Meaningful Representation in Clinical Trials

Presenter: Bram Zuckerman

March 20, 2023

Presentation THT 2023

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

Presenter: Navin Kapur

March 20, 2023

Presentation THT 2023

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Presenter: Gregg Stone

March 20, 2023

Presentation THT 2023

What Are Clinically Meaningful and Practical Pivotal Trial Endpoints for Effectiveness and Safety to Demonstrate an Acceptable Benefit-Risk Profile?

Presenter: Maria Rosa Costanzo

March 20, 2023

Presentation THT 2023

SEISMiC Trial: Isatroxime (lusi-inotrope) (HF shock)

Presenter: Alexandre Mebazaa

March 20, 2023

Presentation THT 2023

SSO2 for AMI Shock: The ISO-Shock Trial (AMI)

Presenter: Babar Basir

March 20, 2023

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

News Conference News THT 2022

PA Pressure Monitoring Useful Even in Presymptomatic CHF Patients

L.A. McKeown

February 03, 2022

Presentation THT 2022

Executing Clinical Follow Up In the Modern Era

Presenter: Jodi Akin

February 02, 2022

Presentation THT 2022

Clinical Trials During COVID-19: Innvestigator Perspective

Presenter: Scott Solomon

February 02, 2022

Presentation THT 2022

Research Consortium / Collabratories

Presenter: Mona Fiuzat

February 02, 2022

Presentation THT 2022

Challenges With Cardiogenic Shock Studies in the US

Presenter: Chuck Simonton

February 02, 2022

Presentation THT 2022

Innovation in Heart Failure Trial Designs

Presenter: Ori Ben-Yehuda

February 02, 2022

Presentation THT 2022

Heart Failure Trials in the Modern Era: Where Are We Going?

Presenter: Andrew Farb

February 02, 2022

Presentation THT 2022

Efficacy of Hemodynamic-Guided Heart Failure Management in Patients Enrolled With Elevated Natriuretic Peptide Levels but Without a Recent HF Hospitalization: An Analysis of the GUIDE-HF Trial

Presenter: Akshay Desai

February 02, 2022

News Conference News THT 2022

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Shelley Wood

February 01, 2022

Presentation THT 2022

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Presenter: Barry Greenberg

February 01, 2022

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Featured Lecture: How to Incorporate New Therapies and In What Order -- Ahead of the Guidelines

Presenter: Milton Packer

February 01, 2022

Advertisement

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

FDA Guidance on Meaningful Representation in Clinical Trials

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

What Are Clinically Meaningful and Practical Pivotal Trial Endpoints for Effectiveness and Safety to Demonstrate an Acceptable Benefit-Risk Profile?

SEISMiC Trial: Isatroxime (lusi-inotrope) (HF shock)

SSO2 for AMI Shock: The ISO-Shock Trial (AMI)

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

PA Pressure Monitoring Useful Even in Presymptomatic CHF Patients

Executing Clinical Follow Up In the Modern Era

Clinical Trials During COVID-19: Innvestigator Perspective

Research Consortium / Collabratories

Challenges With Cardiogenic Shock Studies in the US

Innovation in Heart Failure Trial Designs

Heart Failure Trials in the Modern Era: Where Are We Going?

Efficacy of Hemodynamic-Guided Heart Failure Management in Patients Enrolled With Elevated Natriuretic Peptide Levels but Without a Recent HF Hospitalization: An Analysis of the GUIDE-HF Trial

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Results From First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Featured Lecture: How to Incorporate New Therapies and In What Order -- Ahead of the Guidelines

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content